Darvas / Guttman / Dormán Chemical Genomics and Proteomics, Second Edition

2. Auflage 2013
ISBN: 978-1-4398-3059-8
Verlag: Taylor & Francis
Format: PDF
Kopierschutz: Adobe DRM (»Systemvoraussetzungen)

E-Book, Englisch, 243 Seiten

Since the publication of the pioneering first edition of Chemical Genomics and Proteomics more than seven years ago, the area of chemical genomics has rapidly expanded and diversified to numerous novel methods and subdisciplines, such as chemical glycomics and lipidomics. This second edition has been updated to uniquely reflect this interdisciplinary feature as well as the remarkable developments that have occurred. The new edition also covers innovative applications from cell biology to drug discovery to, more recently, clinical diagnostics and medical practice, which utilize the concepts of chemical genomics.

The text provides an overview of the strategies and methodologies of chemical genomics, focusing on emerging technologies and recent applications in the areas of combination chemical genetics, toxicogenomics, drug chemical genomics and proteomics, and orthogonal chemical genetics. It describes the development and application of novel analytical methods used in lipodomics, such as steroidomics. The book also discusses biomarker discovery applications of microarray technologies using DNA, RNA, and protein and glycan arrays. Chapters cover further applications of biomolecular biomarkers for disease diagnosis, in small molecule drug R&D, and during therapeutic use of medicines. These include prognostic, disease specific, response (surrogate), and toxicity biomarkers.

In addition, the text explores the principles of contemporary systems biology and genomics in experimental medicine—a new paradigm that demonstrates a network-oriented view and advanced statistical and informatics data management, opening the way toward personalized medicine. Finally, various in silico chemogenomics approaches are addressed for predicting binding of drug candidates to undesirable targets, which would help in designing better clinical candidates with fewer side effects. This new edition benefits a broad range of readers from industrial and academic researchers in drug discovery, medicinal chemistry, and molecular and cell biology to physicians in clinical diagnostics and students in related fields of study.

Zielgruppe

Practitioners and scientists in drug discovery, medicinal chemistry, and molecular/cell biology; physicians in diagnostics and clinical practice; experts in the drug development pipeline; undergraduate and graduate students; and professors teaching courses in medicinal chemistry, pharmacy, and medicine.

Autoren/Hrsg.

Darvas, Ferenc

Guttman, András

Dormán, György

Fachgebiete

• Naturwissenschaften Biowissenschaften Biowissenschaften Genetik und Genomik (nichtmedizinisch)
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Medizin, Gesundheitswesen Medizinische Mathematik & Informatik
• Naturwissenschaften Biowissenschaften Biochemie (nichtmedizinisch)
• Mathematik | Informatik EDV | Informatik Angewandte Informatik Bioinformatik
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Vorklinische Medizin: Grundlagenfächer Humangenetik
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Pharmazie
• Naturwissenschaften Biowissenschaften Angewandte Biologie Bioinformatik

Inhaltsverzeichnis

Utilizing small molecules in chemical genomics: Toward high-throughput (HT) approaches
György Dormán and Ferenc Darvas

Development and application of novel analytical methods in lipidomics
Yuqin Wang, Anna Meljon, Michael Ogundare, and William J. Griffiths

From chemical genomics to chemical proteomics: The power of microarray technology
Sándor Spisák and András Guttman

Genomic and proteomic biomarkers in the drug R&D process
László Takács, Anna Debreceni, and István Kurucz

Quo vadis biomedical sciences in the omics era: Toward computational biology and medicine
András Falus, Éva Pállinger, Gergely Tölgyesi, Viktor Molnar, Tamás Szabó, Edit Buzás, Katalin Éder, Peter Antal, and Csaba Szalai

Novel chemogenomic approaches to drug design
Didier Rognan